Skip to Content

News Releases

News Releases

Date Title and Summary
Toggle Summary Chronimed Reports Fiscal 2000 Third Quarter Results
Click here for a printable version in PDF   NEWS RELEASE April 25, 2000 Contacts:  Paul S. Dunn, Investor Relations, or Maurice R. Taylor, II, Chairman and CEO, at Chronimed Inc. (612) 979-3600 CHRONIMED REPORTS FISCAL 2000 THIRD QUARTER RESULTS Operating Income for Combined Company Hits $0.10 per
Toggle Summary Chronimed Announces Intent To Spin-Off Diagnostic Products Unit
Company Discontinues PaineWebber Engagement MINNEAPOLIS, March 13, 2000 -- Chronimed Inc.'s (Nasdaq: CHMD)Board of Directors today announced its intent to spin-off its Diagnostic Products business through a tax free dividend to shareholders. The dividend will provide shares in the newly formed
Toggle Summary Chronimed Reports Fiscal 2000 Second Quarter Results
Click here for a printable version in PDF   NEWS RELEASE January 24, 2000 Contacts:  Paul S. Dunn, Investor Relations, or Maurice R. Taylor, II, Chairman and CEO, at Chronimed Inc. (612) 979-3600 CHRONIMED REPORTS FISCAL 2000 SECOND QUARTER RESULTS Company Reports Record Revenue and Continued
Toggle Summary Chronimed Selected To Provide Specialty Pharmacy Services To Mutual Of Omaha Members
Agreement Provides Access to 1.3 million Mutual of Omaha Members MINNEAPOLIS, December 15, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today that it signed a contract with Mutual of Omaha for the distribution of transplant and injectable medications.
Toggle Summary Chronimed Awarded Sole Source Blood Glucose Test Strip Contract By Beverly Enterprises
Two-year agreement allows for distribution of blood glucose monitors and related products MINNEAPOLIS, November 1, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today that it received a sole source contract from Fort Smith, AR-based Beverly Enterprises, Inc.
Toggle Summary Chronimed Reports Fiscal 2000 First Quarter Results
Click here for a printable version in PDF   NEWS RELEASE October 27, 1999 Contacts:  Paul S. Dunn, Investor Relations, or Maurice R. Taylor, II, Chairman and CEO, at Chronimed Inc. (612) 979-3600 CHRONIMED REPORTS FISCAL 2000 FIRST QUARTER RESULTS Company Reports Record Revenue and Improved
Toggle Summary Chronimed To Manage Fda Clinical Trials For Visible Genetics' Hiv Genotyping Test
MINNEAPOLIS, October 13, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today that it has signed a contract with Visible Genetics Inc. (Nasdaq:VGIN) whereby Chronimed's wholly-owned subsidiary, Clinical Partners, will manage Visible Genetics' prospective multi-center, controlled clinical trial of
Toggle Summary Chronimed Reports Fiscal 1999 Fourth Quarter And Year End Results
MINNEAPOLIS, August 10, 1999 -- Chronimed Inc. (Nasdaq: CHMD),today announced fourth quarter and year end results for the period ended July 2, 1999. For the fourth quarter, Chronimed reported record revenue of $55.3 million, up 36 percent from $40.5 million last year.
Toggle Summary Chronimed Selected To Provide Transplant Medication Management Program For Prudential Healthcare Members
MINNEAPOLIS, June 16, 1999 -- Chronimed Inc. (Nasdaq: CHMD) announced today that Prudential HealthCare has selected the Chronimed Life Management Program SM to manage the medication regimens of its approximately 4,000 current transplant members and all future members who receive transplants.
Toggle Summary Chronimed Selected To Provide Transplant Medication Management Program For Prudential Healthcare Members
MINNEAPOLIS, June 16, 1999 -- Chronimed Inc. (Nasdaq: CHMD) announced today that Prudential HealthCare has selected the Chronimed Life Management Program SM to manage the medication regimens of its approximately 4,000 current transplant members and all future members who receive transplants.